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Abstract
In the last few years various methods are being applied in the use of platelet-rich plasma
(PRP) during treatment in different orthopedic disease and sports trauma. They allow im‐
provement of local biological condition and regeneration of different types of tissues.
PRP is a modern treatment strategy with worldwide recognition. There is a high concen‐
tration of platelet growth factors in small amounts of plasma. PRP and its various forms
have become one of the best methods to support the healing process of various tissues.
PRP is used in regenerative medicine, because it provides two of three components
(growth factors and scaffolds) necessary for complete tissue regeneration. The particular
reason for the appearance of lesions is important in order to select an appropriate treat‐
ment method and technical application. Main indications are acute and chronic wounds,
pseudarthrosis, ligament and muscle injuries, some tendinopathies, osteoarthritis, chon‐
dral injuries.
Keywords: Platelet rich plasma, platelets, platelet growth factors, chronic skin wounds
1. Introduction
Platelet-rich plasma (PRP) is a modern treatment strategy with worldwide recognition. PRP
was introduced in the 1950s and is currently used in multiple fields of medicine. There is high
concentration of platelet growth factors in small amounts of plasma. This works for offering
an ''ideal environment'' for tissue regeneration and is part of the so-called biological therapy.
The PRP implementation is an autologous therapy, which eliminates the risk of blood-borne
infections. PRP and its various forms has become one of the best methods to support the healing
process of various tissues. The term „regenerative medicine” was introduced in the 1990s.
Many studies related to stem cells, growth factors, and extracellular matrix support the
development of this new treatment philosophy. It differs from classic tissue engineering,
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where tissue regenerates ex vivo. Here, the major idea is regeneration of fully functional tissue
on the spot, while damaged tissue is provided for by cellular elements and the process is
managed by local factors. PRP appears to be the main source of autologous products in
regenerative medicine and a true precursor and foundation of the healing process along with
scaffold and stem cells [1]. PRP is used in regenerative medicine, because it provides two of
the three components (growth factors and scaffolds), necessary for complete tissue regenera‐
tion. This review discusses the state-of the-art-studies on PRP action mechanisms in surgical
and non-surgical implementation (treatment of tendon injuries, cartilage damage, muscle
trauma, cartilage and bone pathologies, and wound healing).
2. Platelet biology
Platelets are blood cells formed during hematopoiesis. They are built from cytoplasmic
fragments of the long extensions of megakaryocytes and are small, discoid, and anucleate cells
[2]. These extensions are interwoven through bone marrow sinusoids and are fragmented by
shear forces, thus forming new platelets in the blood [3]. Their circulating lifespan is 5-9 days
and their major clearance mechanism is via Kuppfer cells and hepatocytes. This became known
after discovering the lectin receptor on the cell surface [4]. It is known that the functional
activity of platelets changes depending on their size and age, as younger and larger platelets
demonstrate better hemostatic function unlike smaller and older cells [5,6,7]. Platelets measure
from 1 to 4 µm in diameter and apart from being anucleated, they contain different organelles.
They are discoid or ellipsoid in shape and have three distinguishable zones: peripheral or outer
zone, organelle zone, and cytosol zone.
Peripheral zone – This is the outermost section and it contains antigens, glycoproteins and
various enzymes. This zone connects the platelets with other cells and blood vessel linings.
Large quantities of plasma proteins and coagulation factors are firmly attached to this surface.
Inside the membrane there are proteins (mostly glycoproteins and a small amount of carbo‐
hydrates). This membrane contains a double-layer of phospholipids, cholesterol and glycoli‐
pids. Glycoproteins have a number of specific receptors for certain coagulation factors, such
as GPIb (thrombin receptors) and the von Willerband factor. The GPIIbIIIa complex is formed
from glycoproteins IIb and IIIa and it acts as a fibrinogen receptor. Platelet adhesion and
aggregation is affected by those glycoproteins [8].
Organelle zone – It is built from a variety of structures: dense granules, alpha granules, Golgi
apparatus, dense tubular system and open canalicular system, lysosomes and mitochondria.
The dense granules (or dense bodies) are dense structures containing 65% of the total platelet
adenosine-diphosphate and adenosintriphosphate. Serotonin, pyrophosphate, antiplasmin
and large amounts of calcium, necessary for platelet aggregation are also stored there [8-10].
Alpha granules contain various growth factors (platelet-derived growth factor— PDGF,
transforming growth factor beta—TGF-b, etc.), and clotting factors. Many of the 30 bioactive
proteins, playing a key role for hemostasis are contained in these granules; hemostasis is
considered to be the first stage of wound healing [11,12].
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Upon platelet activation, internal membrane systems including the dense tubular system (DTS)
and the open canalicular system (OCS) interact. By means of cellular membrane invaginations,
the open canalicular system helps the communication between the endoplasm and the external
milieu. The mitochondria synthesize ATP, which is functionally very important. Acid phos‐
phatize enzymes, glucosamidase, and galactosidase are contained in the lysosomes. Many
particles contain glycogen, thus storing energy for cells. The Golgi apparatus is part of the
membrane system as well [8,13].
Cytosol zone - It contains microtubules and forms a circumferential zone around platelets.
Microtubules are connected to microfilaments. This is how the platelet cytoskeleton is formed;
it directs the cell’s movement, eliminates secreted products, and retracts clots. Upon platelet
activation microtubules could be seen in platelet pseudopods [8].
3. Functions of the platelets
Besides participation in hemostasis, platelets also have other functions. To obtain hemostasis,
the interaction of three main mechanisms is necessary: vascular response, platelet activity, and
clot formation. When platelets are not activated by various stimuli, they are present in blood
circulation in a state of quiescence in disc-shape form. The variety of stimuli can comprise
physical or chemical ones, or a combination of both. The sub-endothelial collagen forming in
the wound as a result of trauma, along with the von Willebrand factor(vWF), are the main
factors that activate blood platelets in vivo, as well as thrombin, adenosine diphosphate, or a
combination of them.
In experimental conditions the major activators for the study of platelets are collagen, thrombin
and adenosine diphosphate, as well as their synthetic substitutes and calcium ions. Integrin
A2b1, glycoproteins complex Ib-V-IX (GPIb-V-IX), and glycoprotein VI (GPVI) are the main
collagen receptors. The involvement of collagen by these receptors is done as follows: after the
process of binding of von Willebrand factor to glycoprotein Ib (GPIb), the exposed collagen
binds to glycoprotein V (GPV) in the same complex, thus slowing down the platelets for a time,
sufficient to allow for the further binding of the integrin a2b1 and glycoprotein VI (GPVI) with
collagen [7,14].
According to Mehta et al., tissue damage leads to vascular exposure. Thus activating platelets
and forming platelet plugs and blood clots. This is how natural hemostasis is provided. This
naturally occurring hematoms consists of 95% red blood cells, 4% platelets, and 1% white blood
cells. An analysis of a platelet-rich clot shows significant differences in composition as
compared to naturally occurring clot, with 95% platelets, 4% red blood cells and about 1%
white blood cells [15].
Platelets also have non-hemostatic functions. In addition to their primary role in hemostasis,
platelets participate in many non-hemostatic processes. Their secretion contains many
different substances [16]. On their external layer, a number of surface receptors are arranged,
including adhesion proteins, cytokines, and lipopolysaccharide [17]. Interesting is the fact that
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platelets also release various substances depending on the stimuli, by which they are activated
[16,18]. Alpha granules contain many substances with directly opposing activities. This implies
the existence of a mechanism for specific release of only a specific content of the granule, which
is possible, but this is still not well studied [19,20]. Inflammation, immunity, and tissue
recovery are some of the most characteristic features of platelets [7].
4. Platelet-Rich Plasma (PRP)
The PRP as a concept can be represented as the volume fraction of blood plasma, where the
platelet concentration is increased compared to the baseline serum level. In platelet rich
plasma, besides platelet concentrate, small amounts of white blood cells are also present and
other blood components as well. Ideal is a concentration of 1,407,640 cells in microliter (with
a standard deviation of 320.100) [21]. This value corresponds to a number of platelets, approx‐
imately five times higher than the normal, nomber in the blood, which is usually in the range
of 150,000 to 350,000 cells in microliter (approximately an average value of about 200,000 cells
in microliter) [22].
Marx et al. suggest that in order to obtain effective treatment with PRP, the approximate
number of platelets should be about 1,000x103 platelets in microliter in volume of a 5 ml
plasma [23,24]. Jacobson et al. studied the influence of higher than five times the platelet
concentration and suggested that angiogenesis is initiated at concentrations of platelet rich
plasma from 1,500x103  platelets  in  microliter  and continues  up  to  3,000x103  platelets  in
microliter. Interestingly, at concentrations of 5,000x103 platelets in microliter, inhibition of
angiogenesis is observed. They reached the conclusion that additional laboratory studies
are necessary to elucidate the optimal concentration for use with a particular pathology.
Concentration of the platelets less than 300x103  platelets in microliter is called ''low'', 300
-800x103 platelets in microliter is considered ''moderate'', and >800x103 platelets in microli‐
ter is called ''high'' [7,25].
The presence of white blood cells in PRP may affect its use, independent of the concentration
of the platelets [26]. The presence of the layer of leukocytes has led to the current classification,
which distinguishes a clean (without leukocytes) PRP, identical to the platelet rich plasma of
Anitua, and PRP with leukocytes. Also present in the classification the fibrin-rich gel known
as a clean, without leukocytes, platelet-rich fibrin, and platelet-rich fibrin with leukocytes or
Choukroun type [27,28].
Ehrenfest et al. categorized the kits based on their fibrin and leukocytes content.
• Pure platelet-rich plasma (P-PRP): cell separator PRP, Vivostat PRF, or Anitua’s
• PRGF;
• Platelet-rich and leukocyte-rich plasma (L-PRP): Curasan, Regen, Plateltex,
• SmartPReP, PCCS, Magellan, or GPS PRP;
• Pure platelet-rich fibrin (P-PRF) Fibrinet;
Immunopathology and Immunomodulation176
• Platelet-rich and leukocyte-rich fibrin (L-PRF): Choukroun’s PRF [27,29].
This classification, despite the various comments, is an important step towards the systemat‐
ization of knowledge, which allows for more objective comparisons of the results of treatment.
It is necessary in future therapy with PRP to choose the allegedly most appropriate kit for the
particular pathology [29].
PRP is an autologous therapy, which stimulates the healing of tissues and positively influences
the recovery processes. It ensures a high concentration of platelets in a small volume of plasma.
Once platelets are activated, platelet aggregation occurs and the contents of their solid granules
and alpha granules is released [30,31]. In order to release the growth factors of the platelets,
PRP must be activated to start the clotting cascade. The activation of platelets in vivo is done
in three ways: by adenosine diphosphate, via membrane phospholipids system (arachidonic
acid), and by inducing the presence of thrombin [32]. In hospital and clinical conditions, the
conversion of prothrombin to thrombin takes place by means of calcium dichloride and thus
platelets are activated. Another way is by means of autologous or bovine thrombin [25].
In order for the platelets and the PRP to be sufficiently functional, they should be activated as
with tissue injury. As a result platelets release their contents and a cascade of events is initiated.
Normal collagen is repaired. Collagen repair consists of the following phases: inflammation,
proliferation, and remodelling [33,34]. Each of these stages is needed to restore the normal
function of the tissue.
The first phase may last up to three days. The growth factors are released during this phase.
Then fibroblasts penetrate and initiate the second phase of wound healing. At this phase
fibroblast differentiation and neovascularization are observed. During the third phase collagen
matures and strengthens as this process may last over a year [33-35].
5. Cascade of wound healing
Wound healing is a complex process that comprises of a sequence of events, starting from the
time of injury and lasting several months, which can be divided into three phases: inflamma‐
tion, proliferation, and remodeling [10,36,37].
In the inflammatory phase is observed at the beginning of the cascade with the activation and
aggregation of platelets and the formation of a fibrin matrix. With platelets degranulation,
cytokines are released that guide the healing process. Leukocytes are attracted by the cytokines
through hemostasis and migrate to the damaged area. The first leukocytes involved and
responsible for the initial wound cleaning are the neutrophils, which eliminate the bacterial
and cellular waste [36,38,39].
During the proliferative phase, which spans through the next few days, monocytes migrate to
the wound area under the influence of chemical signals from growth factors. The differenti‐
ating of macrophages by circulating monocytes is observed. Platelet signaling and modulation
function are also performed by the macrophages. Gradually, the damaged area is impover‐
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ished of platelets. The macrophages clean the area through phagocytosis and secrete factors
responsible for the formation of granulation tissue from the fibroblasts. During this phase,
angiogenesis also begins under the influence of growth factors and thrombin. With the
recovery of vascular endothelial cells new vessels also develop. Endothelial cells are activated
by thrombin, while a process of interaction is also ensured, which restricts the intensity of the
formation of new vessels [40]. In this phase mesenchymal stem cells also emerge and their
differentiation is performed in specific tissues such as bone, cartilage, or vascular tissues being
determined by chemical signals [36,38,39].
At the time of the remodeling phase, contraction of the collagen and convergence of the edges
of the wound is observed. Cell density and vascularization is reduced, excess matrix is
removed, and the collagen fibrils are aligned along the stress lines, which increases the strength
of the newly-formed tissue [10]. Accumulated granulation tissue remodels or slowly trans‐
forms into a specific tissue such as skin or bone [36,38,39].
6. Platelet growth factors
A number of growth factors are located in platelet alpha-granules. In order to be released into
the injured tissue monocytes, neutrophils, fibroblasts, mesenchymal stem cells and osteoblasts
need the chemotactic effect of an available growth factor. Platelet-derived growth factor
(PDGF) produces such effect. This growth factor influences mitogenesis of fibroblasts and
smooth muscle cells. PDGF improves the formation of fibrous tissue, assists in the three phases
of the healing cascade, and also significantly affects angiogenesis and re-epithelialization.
Another important growth factor is transforming growth factor beta (TGF-b). It impacts the
connection between fibronectins. It influences cell migration, proliferation and replication, and
is present during inflammation processes [41].
Chronic wounds’ and endochondral ossification’s healing processes are highly influenced by
vascular endothelial growth factor (VEGF). It is active in angiogenesis, too [13,42]. The next
factor taking part in the recovery of chronic wounds is epidermal growth factor (EGF). It also
influences the mitogenesis of endothelial cells, fibroblasts, and keratinocytes [42]. Hepatocite
growth factor (HGF) is located in various tissues (several types of epithelium, liver, lung,
kidney and tumor). It affects tissue regeneration and possesses morphogenic, mitogenic,
antiapoptotic, and neurotrophic qualities [38,43-46].
7. Application of PRP in the treatment of chronic wounds
The process of healing of skin wounds is very intense and includes a number of phenomena,
such as hemostasis, inflammation, formation of granulation tissue, epithelialization, neovas‐
cularization, collagen synthesis, and wound contraction. Several studies demonstrate that the
growth factors are depleted in chronic wounds. Platelets have a tendency to aggregate when
activated, having a leading role in skin healing. Activated platelets release growth factors,
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adhesion molecules, and lipids through which migration, proliferation, and the function of
keratinocytes, fibroblasts, and endothelial cells are regulated [47].
Skin wounds are defined as the absence of tissue, where epidermis and dermis are affected,
while sometimes can reach the adipose tissue and muscle fascia. In this process, no natural
regeneration is observed and tissue lesion is transformed into fibrotic scarring [48,49]. Skin
wounds have a frequency of 0.78% and huge funts are spent for their treatment. Annually, 2%
of the budget is used for health in the European Union (EU), £ 40 million in the UK, $-1.3 billion
are used for the treatment of decubitus in the US [48].
According to Zhu et al., chronic cutaneous wounds are quite frequent in developing countries.
They are difficult to treat due to insufficient amount of growth factors. Sometimes wound
infections are observed. Conventional treatment with various known techniques and methods
is not enough due to the insufficiency of growth factors. Dressing and surgical debridement
is used for these patients, but these strategies do not lead to significant outcomes [50].
For the development of skin wounds facilitate various etiological factors such as: chronic
venous disease, peripheral arterial disease, neuropathy, arterial hypertension, physical injury,
hematologic disorders, skin infection, inflammatory diseases, neoplasms, iatrogenic changes,
and those associated with nutrition [48,49,51].
PRP gel has been used for wound healing stimulation on molecular and cellular levels for the
last two decades [48,52]. Martinez-Zapata et al. showed tissue regeneration in maxillofacial
surgery, chronic ulcers, and surgical wounds in their systematic review [53]. Weglein et al.
assessed studies dealing with diabetic wound healing and another study reviewed the healing
of chronic wounds [24]. Carter et al. reviewed wound healing when PRP gel is applied and
wound healing of control groups (conventional wound care) and reported on a number of
indicators [48,52].
With these studies, it was observed that PRPs have effectively stimulated healing in wounds
with delayed healing. In a study, Martinez-Zapata et al. reported that the percentage of full
healing of wounds treated with PRP has increased compared to that of control wounds. Carter
et al. performed a meta-analysis of articles for chronic wounds and support the idea that the
use of platelet rich plasma favors full healing compared to control groups [9,19,43]. In a study
by Villela et al., they reached similar conclusions, with one of their conclusions reaching so far
as to conclude that PRP is the method of choice for the treatment of wounds [48,21].
Difficult to heal wounds are considered those that do not heal after the fourth week of their
appearance after being treated with standard methods for the particular pathology. Chronic
is a wound that is not healing for a period of three months. The evaluation of each wound is
very important. For the purpose, a number of point scales suggested by Cancela et al. based
on clinical and anatomical criteria for the size of the wound are used, while a patient variable
is also taken into account. The points are randomly defined using clinical experience in wound
healing. Common parameters are assessed such as the presence or absence of erythema and
edema surrounding the wound, purulent discharge, presence of fibrin, swelling in pressure,
swelling with ocher dermatitis, and granulation [48].
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Anatomical features are noted and graded such as open bone or tendon, location of the wound,
and quality of the pulse of artery dorsalis pedis and artery tibialis posterior (when related to
wound location) [48]. Wounds are measured to determine their overall surface, depth, and
distribution of undermining of the wound edges. The duration of the wound is determined
by the history [48].
There are many studies relating to the pathophysiology of wounds. Skin wound healing is an
intensive process and in it are observed a number of events such as hemostasis, inflammation,
formation of granulation tissue, formation of new vessels, collagen synthesis, epithelialization,
and contraction of the wound. The process of reduction of growth factors in chronic wounds
is demonstrated in numerous reports as a result of their reduced production and release,
sequestration, or degradation. These mechanisms can be combined [48,54].
Platelet aggregation has a clearly expressed effect in the process of skin wound healing. In this
process, growth factors are released and, adhesion of molecules and lipids is observed, while
they are responsible for the regulation of cellular migration, proliferation and function of
keratinocytes, fibroblasts, and endothelial cells [11,55]. Platelets secrete several antimicrobial
peptides when activated by thrombin. PRP has an important antimicrobial and immunoregu‐
latory activity obtained from leukocytes [56,57]. A review of studies using different products
rich in platelets demonstrates significant improvement in the treatment of chronic wounds.
Anitua et al. presented an open and randomized study to evaluate the effect of PRP in chronic
ulcers of 14 patients. They reported good healing response in 80% of the cases after 8 weeks of
treatment, compared with 20% in the control group. Leukocytes were not detected in the
analyzed products. Their explanation for the good results lies in the high concentrations of
growth factors [48,54].
Crovetti et al. monitored the evolution of chronic skin wounds in 24 patients treated with
autologous or homologous gel (depending on the case) and observed a complete healing in 9
of them after an average of 10 applications, with a reduction of pain in all cases [48,49].
Marté-Mestre et al. reported the recovery of vascular chronic ulcers with the use of PRP in 12
of 14 patients for an average treatment period of 2.93 months (average of 0.5 - 7 months) [48,58].
Dellinger and Britton applied autologous platelet gel and reported positive results, with no
complications and acceleration of the healing process (5 - 8 weeks) regardless of Pan size. A
reduction of the risk of amputation and improvement of quality of life was observed [22,48].
PRP has the advantage of having no adverse effects [59].
Margolis et al. found in a retrospective group study with neuropathic wounds in diabetic feet
greater efficiency in the use of PRP against the conventional therapies, with a more obvious
effect in severe wounds [48,60].
PRP may be used for treatment of various chronic cutaneous wounds, especially when
standard conventional therapy is not good enough and surgical treatment is not possible. It
reduces the duration, cost of treatment and the hospital stay. These procedures may be
performed in outpatient clinics. There is reduction of wound pain after starting the treatment,
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reduced risk of blood-borne disease transmission, wound healing is restored, and local
immunity is activated [61,62].
8. PRP in osteoarthritis
Cartilage defects and the most common joint disease, osteoarthritis(OA), are characterized by
degeneration of the articular cartilage that ultimately leads to joint destruction [50]. Several
treatments for OA exist, including exercise, weight control, bracing, nonsteroidal anti-
inflammatories, cortisone shots, and viscosupplementation. The biochemical environment of
the disease process should be influenced in order to achieve better control of the symptoms.
There is an imbalance between various cytokines resulting in the increased quantity of
proteolytic enzymes leading to cartilage destruction [25,63 - 65]. The repair of damaged
articular cartilage and bone defects represents a great challenge for the orthopedist because of
the regenerative limitations of cartilage and the difficulty in obtaining an adequate bone
substitute. Damages to the cartilage havess been treated by microfracture, debridement, and
grafting procedures [42]. The results obtained by these techniques are so far unsatisfactory,
and in most cases, these techniques result in deposition of fibrous connective tissue with low
mechanical strength at the defect location [56,66]. Broad application of PRP is typical for oral,
maxillofacial, and plastic surgery, while in the last few years there have been papers showing
administrations in orthopedics and traumatology. When obtaining PRP, high concentration of
growth factors in a volume unit is observed and acceleration of the regeneration process in the
arthritic cartilage. Consecutively, PRP stimulates local cell activity. This technique is low-
priced and has no side-effects or dangers for the patient [33,67].
The presence of concentrated growth factors modulates the phenotypic expression of chon‐
drocytes. This improves their recovery. TGF-b plays a major role in the differentiation of stem
cells into chondrocytes. Synthesis of cartilaginous matrix is improved, as well. PDGF and IGF
are both key parts of the recovery process, as the first one stimulates proliferation of chondro‐
cytes while the second one increases the synthesis of proteoglycan - macromolecules. Thus,
the strength of cartilage is improved [30,56]. Not only does PRP stimulate cellular activity and
the process of regeneration and repair, but it also improves bone and cartilage recovery when
biomaterials are applied [68,69]. In order to recover cartilage defects, not only PRP is needed
but also an adequate biomaterial that has similar characteristics as the natural tissue and
promotes cellular adhesion, proliferation, and differentiation [56].
According to Hunziker et al., TGF-b increases chondrogenesis [24,70], while Kon et al.
documented PRP amplification of chondrocyte proliferation with convincing clinical effects
on degenerative knee OA [24,25,70,71]. Results of the Kon et al. publication on 115 arthritic
knees treated with PRP showed improvement in the functional status and pain scores “which
remained positive at 6 months, with only mild degradation of scores at 1 year”. It was also
mentioned that lower grades of arthritis and younger patients had better outcomes [25,72].
Qi et al. shared results on the treatment of osteochondral defects in rabbits with PRP and
biodegradable collagen scaffolds. PRP was put into collagen scaffolds (0.05 ml PRP/structure)
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and then implanted in osteochondral defects (4 x 3 mm) produced in the patellar sulcus of
rabbit femurs. Evaluation of tissues was completed after 6 and 12 weeks by histological analysis
and a mechanical indentation test. The results in both follow-up times were improved and
showed that PRP possesses the capacity to stimulate the regeneration of critical defects in
cartilage [56,73].
According to Patel et al. in a study with level 1 evidence, PRP has a superior effect compared
to placebo in patients with varying degrees of knee OA. They tested 78 patients (156 knees)
and observed that PRP alleviated the symptoms of OA when compared with a saline injection
used as control. Follow-up period was up to 6 months. The results showed that with the help
of PRP, the homeostasis and function of the knee joint can be improved [74,75].
Wei et al. reported the effect of PRP on the regeneration of cartilage in vivo. Auricular cartilage
chondrocytes from rabbits were added to PRP (5 x 107 cells/ml PRP), injected subcutaneously
in the dorsum of the donor animal, and after 60 days the tissue was evaluated by magnetic
resonance, histological, and histochemical analysis. The results exhibited cartilaginous tissue
formation in those groups that were injected with chondrocytes and PRP. In the groups in
which only PRP was injected, cartilaginous tissue formation was not
observed. The authors inferred that PRP is effective in stimulating regeneration of cartilage
when associated with viable cells [56,76].
A level 1 study published in 2012 in the Journal of Arthroscopy by Sanchez et al. used PRP
type 4A to observe the results of PRP injection compared with hyaluronic acid. In this study
176 patients, were randomized to receive three weekly applications of PRP (8 ml at weekly
intervals) or hyaluronic acid injections. The study was well-conducted, but the results only
focused on the short term (until 6 months of follow up). The study was awarded as the best
randomized clinical trial (level 1) for 2012, which gives useful fundamental guidelines on how
to study the effects of PRP [74,77,78].
In the light of orthopedic and trauma critical literature, there is no standardization of treatment
methods, such that most of the works use 3–5 applications of PRP in intervals ranging from
1–3 weeks with no standardization of the amount of volume to be applied and the ideal platelet
concentration method [74].
Important factors for results of PRP treatment are the amount of platelets, grade of chondrocyte
damage, patient’s physical activity, and medical history combined with psychosocial factors.
It is good to investigate whether PRP balances anabolism-catabolism, and if there is, what effect
of does the PRP have on the synovium. Given the patient’s condition, appropriate PRP
treatment in OA should use more anti-inflammatory cytokines instead of pro-inflammatory
cytokines. The future of OA research aims at isolating cytokines contained in PRP termed as
"autologous conditioned serum" to specifically inhibit IL-1 and TNF alpha and down regulate
MMP-13 [25,79].
Early OA can be treated by implementing intra-articular PRP. Worse outcome is observed with
patients of advanced age and disease process. Khoshbin et al. compared intra-articular
administration of PRP to hyaluronic acid and non-setoroid injections and reported that
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sequential intra-articular PRP injections may have beneficial effects on adult patients with mild
to moderate osteoarthritis for a period of 6 months [80].
Zhu et al. reported the fact that PRP contains growth factors, which may have a negative impact
on the treatment of a joint with osteoarthritis. That is why those growth factors should be
isolated. The following years may be focused on finding suitable and harmless growth factors
to improve PRP outcome [50]. Dold et al. paid attention to the fact that there is insufficient data
on PRP implementation on post-traumatic osteochondral defects. Further studies with long-
term follow-up are necessary in order to illustrate the benefits of isolated PRP application or
application in combination with surgical treatment when treating cartilage pathology [81].
9. Tendinopathies
Efficiency of PRP for treating tendinopathies has been vastly studied, and obtained results
have been mostly positive (both in vitro and in vivo). Other research also supports the use of
PRP for treating tendinopathies through testing cultures of equine and human cells [82,83].
An increase in the types of expression of collagen genes in tendon cell cultures with PRP was
presented in a study by Schnabel et al [84]. Similar results were shown by Mishra and Pavelko
in their study including an improvement in the pain felt by 15 patients with chronic elbow
tendinosis after a single application of PRP [85]. In the PRP-treated group, 93% of the cases
achieved pain reduction. Schepull et al. published the first randomized clinical study on the
use of PRP in complete ruptures of the ankle tendon. Elasticity was evaluated after 7 weeks
and functional assessments were completed after 1 year [86].
Creaney et al. in a recent study concluded that patients with resistant elbow tendinopathy
were also considered appropriate for PRP treatment [87]. According to Peerbooms et al. in a
double-blind study, with a level of evidence 1, the use of PRP in the treatment of chronic lateral
epicondylitis was more favourable than injections of corticoids [88].
A significant statistic improvement at 1 year was observed in the group treated with PRP in
comparison to the corticosteroid group that showed improvement only at the beginning. It can
be inferred that in addition to conservative treatments, PRP provides a viable therapeutic
alternative for refractory tendinopathies (as confirmed in a South Korean study in PRP
treatment resulting in “increased cell proliferation, genic expression and synthesis of the
tendon matrix in degenerative injuries of the rotatory cuff”) [89].
Other findings include the successful use of PRP (alternatively to conservative therapies) in
Achilles tendon injuries in conjunction with stem cells and with other various tendinopathies
of 203 patients (epicondylitis, patellar tendonitis, hamstring origin (ischial tuberosity) tendo‐
nitis, plantar fasciitis, flexor carpi ulnarii tendonitis, pes anserinus tendonitis, biceps femoris
tendonitis, iliopsoas tendonitis, athletic pubalgias, and biceps brachii tendonitis) whose status
did not improve during conservative therapies [90]. Local infiltration with PRP was applied
and 75% success ratio in patients was achieved. According to Virchenko and Aspenberg, and
in another study by Eliasson et al. in Achilles tendon rupture patients, results are better with
percutaneous suture, PRGF placement, and early load-bearing and mobilization [83,91,92].
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10. Anterior Cruciate Ligament (ACL)
As a result of the growing popularity of growth factor treatment techniques, PRP treatment
applications have increased for both soft and bone tissue therapies. Several studies include
positive results from such treatments. Repair of ligament injuries was tested by Sánchez et al.,
resulted in better healing outcomes and fewer complications after applying PRP to 100 patients
with ACL reconstruction [93]. Fixation of the PRPG graft was studied by Radice et al. and the
results were evaluated using MRI images of the interior of the ACL graft and concluded a 48
% faster and completely homogenous repair of the PRPG graft in the experimental group [83,
94,95].
Controversial opinions are shared on the application of PRGF/PRP in the reconstruction of the
ACL and posterior cruciate ligament (PCL), such as the degree of effectiveness in the integra‐
tion of the graft into the bone tunnel and rates of graft maturation [29,94,96]. A statistically
significant difference (p = 0.023) was found during stimulation of both ACL graft maturation
and ACL graft-bone healing with PRP application [93]. After histological assessment of the
ACL grafts with and without PRP, Sanchez et al. found “a significantly better maturity index
for ACL grafts (12 pts vs. 14 pts, p = 0.024), and more newly developed synovial tissue
enveloping the platelet treated grafts (77% of cases) compared to the control grafts without
platelets (40%)” [93].
11. Muscle
The use of PRP in muscle injury treatment still hasn’t been studied thoroughly in humans [74,
97]. There are a number of studies on the effects on muscle tissue. For instance, Shen et al.
stated that the inflammatory phase of skeletal muscle healing was controlled by growth factors,
macrophages, and COX-2 pathway products [90]. According to Sánchez et al. “the clinical
benefits of the ultrasound-guided application of growth factor in physical therapy, electro‐
therapy, and isometric exercise” for athletes include “a decrease in pain and swelling, a
complete recovery of functional capacities before the expected time, and regeneration of the
muscle tissue according to ultrasound”. No evidence of fibrosis and no recurrence of injuries
were found in any of the treated athletes [65,98].
Nevertheless, there still have to be more studies necessary to define the efficiency of PRP in
acute muscle injury treatment and to create adequate protocols for administration. The main
reason is the insufficient number and low methodological quality of the current studies on the
use of PRP in human muscle injuries [38].
12. Surgery and trauma (Autologous fibrin Glue)
The introduction of fibrin glue in repair techniques started in the beginning of the 20th century.
Its main use remains within surgical interventions and undergoes constant modification for
better results. Fibrin glue became the predecessor of contemporary PRP treatment [99].
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A number of studies show the benefits of fibrin and platelet combined treatment. According
to Everts et al., the application of autologous platelet gel and fibrin sealant in total knee
arthroplasty lead to “significant postoperative increases in hemoglobin rates, required less
allogeneic blood, and had fewer complications during wound treatment”, thus showing high
efficiency of treatment method [100]. Levy et al. evaluated the hemostatic efficiency of adhesive
fibrin in 58 patients (a control group and a fibrin treated group) undergoing total knee
arthroplasty. Outcomes were significantly higher blood loss for the control group (24 patients
needed blood transfusion versus only six from the treated group) and no ostoperative adverse
events in the treated group [101]. Sánchez et al.’s findings show the recovery of 12 athletes
treated for total Achilles tendon rupture (six received an association of PRGF), during which
repair was completed significantly faster than that of the control group, needed less time to
recover range of motion and to resume training [102].
It is estimated that few studies have examined PRP action during treatment of orthopedic
trauma [67,103], which shows that common treatment was the combination of PRP with bone
graft, bone marrow and various bone substitutes (tricalcium phosphate, hydroxyapatite bio-
ceramics), as well as treatment with human mesenchymal stem cells in an osteoconductive
environment (platelet gel application used to increase formation of new bone tissue through
modulating and stimulating the healing cell mediators) [67,103-105].
Other studies represent the effect of biological material in the hemostasis after total substitution
of the articulation. According to the results of “98 total arthroplasties of the knee, 61 received
application of PRP in the intraoperatory period on the exposed tissue and on the closure of the
wound at the end of the procedure”. Conclusions showed significant acceleration of recovery
and better overall mobility and quality of life in PRP treated patients. The reasons for such fast
recovery were attributed to the direct PRP application on knee surgery after arthroplasties.
This seals the tissue and takes platelets directly to the wound, where the regeneration process
starts immediately [106].
PRP may be used on patients with factures or in cases of total arthroplasies. With the intro‐
duction of new cement–free implants, the use of PRP between the implant and the bone might
speed up the osteointegration process and improve the implant fixation [38].
13. Conclusion remarks
In the last few years various methods are applied in the use of PRP during treatment in different
orthopedic disease and sports trauma. They allow improvement of local biological condition
and regeneration of different types of tissues. Without doubt the use of PRP is absolutely a
treatment option. According to Werner and Cramer the platelet is the most important cell for
the repair processes of the body [74].
Recently, scientific research and technology have presented a new perspective concerning the
understanding of "orthobiologic" treatments and the healing process of lesions [38].
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PRP treatment is widely applied in the last ten years, especially for stimulating coagulation.
A number of studies show that platelets demonstrate other functions, too. They are connected
to liberating bioactive proteins and growth factors. The bioactive proteins as well as the growth
factors improve tissue regeneration and the process of healing. PRP is the first true biologic
therapy that has hit orthopedics by storm. Its ease of use and generally high safety profile has
made it a preferred option for the most of the physicians and their patients worldwide. When
trauma of musculoskeletal system injuries occur healing takes longer periods of time, and
frequently they do not recover completely. Fast and effective recovery is of particular impor‐
tance for athletes. That’s why all healing methods that accelerate the recovery process are
fundamentally important. Many different pathologies can be treated with PRP.
The administration of PRP in athletes has been gradually introduced in everyday patients. This
has become another option for treatment in addition to conservative options. A number of
surgical manipulations can influence results in PRP treatment, such as grafts, medication, and
physical therapy.
“Following recommendations of the International Olympic Committee (IOC), the local
applications of PRP have been used in the treatment of mild to moderate lesions with no
surgical indication, or during surgery” [107].
Main indications are acute and chronic wounds, pseudarthrosis, ligament and muscle injuries,
some tendinopathies, osteoarthritis, chondral injuries. Almost all the surgeries carried out
since 2007 have used PRP, whether in gel or liquid form [108].
PRP represents an autologous biological material as its action is directly related to general
clinical conditions of the patient. The particular reason for the appearance of lesions is
important in order to select an appropriate treatment method and technical application.
However, standardization in PRP protocols and long-term follow-up should clarify some of
the questions regarding the durability of these procedures and any possible modification that
should be done to achieve better results.
Various additional new studies are necessary to further improve the results of PRP application
in different pathologies. This will help with understanding the different stages of the healing
process and demonstrate the potential of PRP treatment in everyday patients.
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